6M1I

CryoEM structure of human PAC1 receptor in complex with PACAP38

6M1I の概要

• エントリーDOI: 10.2210/pdb6m1i/pdb
• 関連するPDBエントリー: 6M1H
• EMDBエントリー: 30047 30048
• 分子名称: Pituitary adenylate cyclase-activating polypeptide type I receptor, Pituitary adenylate cyclase-activating polypeptide, Nanobody 35, ... (6 entities in total)
• 機能のキーワード: gpcr, protein binding
• 由来する生物種: Homo sapiens; 詳細
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 157595.84

構造登録者

Song, X.,Wang, J.,Zhang, D.,Wang, H.W.,Ma, Y. (登録日: 2020-02-26, 公開日: 2020-03-11, 最終更新日: 2024-11-13)

主引用文献

Wang, J.,Song, X.,Zhang, D.,Chen, X.,Li, X.,Sun, Y.,Li, C.,Song, Y.,Ding, Y.,Ren, R.,Harrington, E.H.,Hu, L.A.,Zhong, W.,Xu, C.,Huang, X.,Wang, H.W.,Ma, Y.
Cryo-EM structures of PAC1 receptor reveal ligand binding mechanism.
Cell Res., 30:436-445, 2020

PubMed Abstract: The pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1R) belongs to the secretin receptor family and is widely distributed in the central neural system and peripheral organs. Abnormal activation of the receptor mediates trigeminovascular activation and sensitization, which is highly related to migraine, making PAC1R a potential therapeutic target. Elucidation of PAC1R activation mechanism would benefit discovery of therapeutic drugs for neuronal disorders. PAC1R activity is governed by pituitary adenylate cyclase-activating polypeptide (PACAP), known as a major vasodilator neuropeptide, and maxadilan, a native peptide from the sand fly, which is also capable of activating the receptor with similar potency. These peptide ligands have divergent sequences yet initiate convergent PAC1R activity. It is of interest to understand the mechanism of PAC1R ligand recognition and receptor activity regulation through structural biology. Here we report two near-atomic resolution cryo-EM structures of PAC1R activated by PACAP38 or maxadilan, providing structural insights into two distinct ligand binding modes. The structures illustrate flexibility of the extracellular domain (ECD) for ligands with distinct conformations, where ECD accommodates ligands in different orientations while extracellular loop 1 (ECL1) protrudes to further anchor the ligand bound in the orthosteric site. By structure-guided molecular modeling and mutagenesis, we tested residues in the ligand-binding pockets and identified clusters of residues that are critical for receptor activity. The structures reported here for the first time elucidate the mechanism of specificity and flexibility of ligand recognition and binding for PAC1R, and provide insights toward the design of therapeutic molecules targeting PAC1R.

PubMed: 32047270
DOI: 10.1038/s41422-020-0280-2

実験手法

ELECTRON MICROSCOPY (3.5 Å)